Generic Name: duvelisib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Verastem

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Copiktra is a PI3K kinase inhibitor approved for relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma.

General Info

Copiktra inhibits phosphatidylinositol-3-kinase (PI3K), an enzyme that is part of signaling pathways that play a role in cell growth and metabolism. It is active against forms of PI3K that are present on cancerous B cells, which grow out of control in people with leukemia and lymphoma.

The DUO clinical trial showed that Copiktra slows disease progression in people with chronic lymphocytic leukemia or small lymphocytic lymphoma. Copiktra received accelerated approval for follicular lymphoma based on promising response rates in the DYNAMO study.


Dosing Info:

Copiktra is taken as a pill twice daily.

Side Effects

Common side effects include diarrhea, skin rash, fatigue, fever and pain. Copiktra can cause depletion of white blood cells (neutropenia), which can lead to infections. Potentially serious side effects include bowel inflammation (colitis), lung inflammation (pneumonitis) and severe skin reactions.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: September 24, 2018